Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Bin Zhao, Sabyasachi Bhattacharya, Qiujing Yu & Serge Y. Fuchs. (2018) Expression of the IFNAR1 chain of type 1 interferon receptor in benign cells protects against progression of acute leukemia. Leukemia & Lymphoma 59:1, pages 171-177.
Read now
Read now
Jonathan Pol, Norma Bloy, Florine Obrist, Alexander Eggermont, Jérôme Galon, Isabelle Cremer, Philippe Erbs, Jean-Marc Limacher, Xavier Preville, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2014) Trial Watch:. OncoImmunology 3:6.
Read now
Read now
Fernando Aranda, Erika Vacchelli, Alexander Eggermont, Jérôme Galon, Catherine Sautès-Fridman, Eric Tartour, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2013) Trial Watch. OncoImmunology 2:12.
Read now
Read now
Articles from other publishers (29)
Ming Yi, Tianye Li, Mengke Niu, Qi Mei, Bin Zhao, Qian Chu, Zhijun Dai & Kongming Wu. (2023) Exploiting innate immunity for cancer immunotherapy. Molecular Cancer 22:1.
Crossref
Crossref
Jing Zhang, Bao Guo, Jia-Hua Chen, Xiao-Jing Liu, Jun-Hui Zhang, Hai-Qing Zhu, Wen-Yan Wang, Zhen-Hai Tang, Bing Wei, Yun-Xia Cao & Lei Zhan. (2023) NLRC5 potentiates anti-tumor CD8+ T cells responses by activating interferon-β in endometrial cancer. Translational Oncology 36, pages 101742.
Crossref
Crossref
Kaito Harada. (2023) Pre-emptive and prophylactic donor lymphocyte infusion following allogeneic stem cell transplantation. International Journal of Hematology 118:2, pages 158-168.
Crossref
Crossref
Peter Holicek, Iva Truxova, Jana Rakova, Cyril Salek, Michal Hensler, Marek Kovar, Milan Reinis, Romana Mikyskova, Josef Pasulka, Sarka Vosahlikova, Hana Remesova, Iva Valentova, Daniel Lysak, Monika Holubova, Petr Kaspar, Jan Prochazka, Lenka Kasikova, Radek Spisek, Lorenzo Galluzzi & Jitka Fucikova. (2023) Type I interferon signaling in malignant blasts contributes to treatment efficacy in AML patients. Cell Death & Disease 14:3.
Crossref
Crossref
Xiaolu Song, Ye Peng, Xiaogang Wang, Qi Chen, Xinyu Lan & Fangfang Shi. (2022) The stimulator of interferon genes (STING) agonists for treating acute myeloid leukemia (AML): current knowledge and future outlook. Clinical and Translational Oncology 25:6, pages 1545-1553.
Crossref
Crossref
Letizia Vitali, Alessandra Merlini, Federica Galvagno, Alessia Proment & Dario Sangiolo. (2022) Biological and Exploitable Crossroads for the Immune Response in Cancer and COVID-19. Biomedicines 10:10, pages 2628.
Crossref
Crossref
Christoph Schwepcke, Lara Kristina Klauer, Diana Deen, Daniel Christoph Amberger, Zuzana Fischer, Fatemeh Doraneh-Gard, Carina Gunsilius, Annika Hirn-Lopez, Tanja Kroell, Johanna Tischer, Melanie Weinmann, Jan-Ole Werner, Andreas Rank, Christoph Schmid & Helga Maria Schmetzer. (2022) Generation of Leukaemia-Derived Dendritic Cells (DCleu) to Improve Anti-Leukaemic Activity in AML: Selection of the Most Efficient Response Modifier Combinations. International Journal of Molecular Sciences 23:15, pages 8333.
Crossref
Crossref
V. A. Shiva Ayyadurai, Prabhakar Deonikar, Kevin G. McLure & Kathleen M. Sakamoto. (2022) Molecular Systems Architecture of Interactome in the Acute Myeloid Leukemia Microenvironment. Cancers 14:3, pages 756.
Crossref
Crossref
Shuang Fan, Meng-Zhu Shen, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Chen-Hua Yan, Huan Chen, Yu-Hong Chen, Wei Han, Feng-Rong Wang, Jing-Zhi Wang, Xiao-Su Zhao, Ya-Zhen Qin, Ying-Jun Chang, Kai-Yan Liu, Xiao-Jun Huang & Xiao-Dong Mo. (2022) Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation. Frontiers in Oncology 11.
Crossref
Crossref
Marcos de Lima, Gail J. Roboz, Uwe Platzbecker, Charles Craddock & Gert Ossenkoppele. (2021) AML and the art of remission maintenance. Blood Reviews 49, pages 100829.
Crossref
Crossref
Mateus de Oliveira Lisboa, Paulo Roberto Slud Brofman, Ana Teresa Schmid-Braz, Aline Rangel-Pozzo & Sabine Mai. (2021) Chromosomal Instability in Acute Myeloid Leukemia. Cancers 13:11, pages 2655.
Crossref
Crossref
Stephanie Sendker, Dirk Reinhardt & Naghmeh Niktoreh. (2021) Redirecting the Immune Microenvironment in Acute Myeloid Leukemia. Cancers 13:6, pages 1423.
Crossref
Crossref
Tobias Bald, Matthew F. Krummel, Mark J. Smyth & Kevin C. Barry. (2020) The NK cell–cancer cycle: advances and new challenges in NK cell–based immunotherapies. Nature Immunology 21:8, pages 835-847.
Crossref
Crossref
Pier Edoardo Rovatti, Valentina Gambacorta, Francesca Lorentino, Fabio Ciceri & Luca Vago. (2020) Mechanisms of Leukemia Immune Evasion and Their Role in Relapse After Haploidentical Hematopoietic Cell Transplantation. Frontiers in Immunology 11.
Crossref
Crossref
Matteo Molica, Massimo Breccia, Roberto Foa, Elias Jabbour & Tapan M. Kadia. (2019) Maintenance therapy in AML: The past, the present and the future. American Journal of Hematology 94:11, pages 1254-1265.
Crossref
Crossref
Annika Hirn Lopez, Diana Deen, Zuzanna Fischer, Alexander Rabe, Christian Ansprenger, Kathy Stein, Valentin Vogt, Julia Schick, Tanja Kroell, Doris Kraemer, Hans-Jochem Kolb, Johanna Tischer, Christoph Schmid & Helga Schmetzer. (2019) Role of Interferon (IFN)α in “Cocktails” for the Generation of (Leukemia-derived) Dendritic Cells (DCleu) From Blasts in Blood From Patients (pts) With Acute Myeloid Leukemia (AML) and the Induction of Antileukemic Reactions. Journal of Immunotherapy 42:5, pages 143-161.
Crossref
Crossref
Xiaodong Mo, Xiaohui Zhang, Lanping Xu, Yu Wang, Chenhua Yan, Huan Chen, Yuhong Chen, Wei Han, Fengrong Wang, Jingzhi Wang, Kaiyan Liu & Xiaojun Huang. (2019) Minimal residual disease-directed immunotherapy for high-risk myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. Frontiers of Medicine 13:3, pages 354-364.
Crossref
Crossref
Xiaodong Mo, Xiaohui Zhang, Lanping Xu, Yu Wang, Chenhua Yan, Huan Chen, Yuhong Chen, Wei Han, Fengrong Wang, Jingzhi Wang, Kaiyan Liu & Xiaojun Huang. (2018) Interferon-α salvage treatment is effective for patients with acute leukemia/myelodysplastic syndrome with unsatisfactory response to minimal residual disease-directed donor lymphocyte infusion after allogeneic hematopoietic stem cell transplantation. Frontiers of Medicine 13:2, pages 238-249.
Crossref
Crossref
Xiao-Dong Mo, Yu Wang, Xiao-Hui Zhang, Lan-Ping Xu, Chen-Hua Yan, Huan Chen, Yu-Hong Chen, Ya-Zhen Qin, Kai-Yan Liu & Xiao-Jun Huang. (2018) Interferon-α Is Effective for Treatment of Minimal Residual Disease in Patients with t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Registry Study. The Oncologist 23:11, pages 1349-1357.
Crossref
Crossref
Xiao-Ji Lin, Hai-ping Dai, Ai-Jing Wang, Feng Chen, Xiao Ma, Ai-Ning Sun, Xia-Ming Zhu, Hui-Ying Qiu, Zheng-Min Jin, Miao Miao, Sheng-Li Xue, Xin-liang Mao, De-Pei Wu & Xiao-Wen Tang. (2018) Effects of preemptive interferon-α monotherapy in acute leukemia patients with relapse tendency after allogeneic hematopoietic stem cell transplantation: a case-control study. Annals of Hematology 97:11, pages 2195-2204.
Crossref
Crossref
Xiao-Dong Mo, Meng Lv & Xiao-Jun Huang. (2017) Preventing relapse after haematopoietic stem cell transplantation for acute leukaemia: the role of post-transplantation minimal residual disease (MRD) monitoring and MRD-directed intervention. British Journal of Haematology 179:2, pages 184-197.
Crossref
Crossref
Zheng-Ping YuJia-Hua DingAi-Ning SunZheng GeBao-An ChenDe-Pei Wu. (2017) A Randomized Study Comparing Stem Cell Transplantation Versus Conventional Therapy for Low- and Intermediate-Risk Myelodysplastic Syndromes Patients. Stem Cells and Development 26:15, pages 1132-1139.
Crossref
Crossref
Xiao-Dong Mo, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Chen-Hua Yan, Huan Chen, Yu-Hong Chen, Wei Han, Feng-Rong Wang, Jing-Zhi Wang, Kai-Yan Liu & Xiao-Jun Huang. (2017) IFN-α Is Effective for Treatment of Minimal Residual Disease in Patients with Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Registry Study. Biology of Blood and Marrow Transplantation 23:8, pages 1303-1310.
Crossref
Crossref
Rebecca Austin, Mark J. Smyth & Steven W. Lane. (2016) Harnessing the immune system in acute myeloid leukaemia. Critical Reviews in Oncology/Hematology 103, pages 62-77.
Crossref
Crossref
Emily Curran, Xiufen Chen, Leticia Corrales, Douglas E. Kline, Thomas W. DubenskyJr.Jr., Priyanka Duttagupta, Marcin Kortylewski & Justin Kline. (2016) STING Pathway Activation Stimulates Potent Immunity against Acute Myeloid Leukemia. Cell Reports 15:11, pages 2357-2366.
Crossref
Crossref
Xiao-Dong Mo, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Chen-Hua Yan, Huan Chen, Yu-Hong Chen, Wei Han, Feng-Rong Wang, Jing-Zhi Wang, Kai-Yan Liu & Xiao-Jun Huang. (2015) Interferon-α: A Potentially Effective Treatment for Minimal Residual Disease in Acute Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 21:11, pages 1939-1947.
Crossref
Crossref
Dolores A. Grosso, Rosemary C. Hess & Mark A. Weiss. (2015) Immunotherapy in acute myeloid leukemia. Cancer 121:16, pages 2689-2704.
Crossref
Crossref
Laurence Zitvogel, Lorenzo Galluzzi, Oliver Kepp, Mark J. Smyth & Guido Kroemer. (2015) Type I interferons in anticancer immunity. Nature Reviews Immunology 15:7, pages 405-414.
Crossref
Crossref
Bin Li, Baolan Sun, Jianwei Zhu, Nina Zhou, Zhiping Yang & Jianhui Gu. (2014) Expression of RKIP in chronic myelogenous leukemia K562 cell and inhibits cell proliferation by regulating the ERK/MAPK pathway. Tumor Biology 35:10, pages 10057-10066.
Crossref
Crossref